For the first time in the world, trials of the lung cancer vaccine launched in seven countries

For the first time in the world, trials of the lung cancer vaccine launched in seven countries.
Doctors have begun testing the world’s first mRNA lung cancer vaccine on patients.
Experts have praised its “unprecedented” potential to save thousands of lives.
Lung cancer is the leading cause of cancer death in the world, with approximately 1.8 million deaths occurring from the disease each year.
Survival rates are particularly poor in people with advanced forms of the disease, where the tumor has spread.
Now experts are testing a new jab that instructs the body to seek out and kill cancer cells — and then prevent them from coming back.
The vaccine, known as BNT116 and developed by BioNTech, is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.
Phase 1 clinical trials, the first human studies of BNT116, have begun at 34 research sites in seven countries: the UK, the US, Germany, Hungary, Poland, Spain, and Turkey.